“Notable is the variable approach to IT MTX in patients requiring therapeutic dose anticoagulation, reflecting clinical decisions of different physicians on a case-by-case basis. Whilst a full discussion of this topic and management of asparaginase-associated [venous thromboembolism] is beyond the scope of this audit, we generally recognize today that many affected patients can be managed to continue therapy as per protocol,” the investigators wrote.
Integrating relevant prescriptions into a single information system, monitoring clinics for treatment backlogs, and improving clinical resources, such as staffing, could help to improve the efficacy of IT MTX therapy, they suggested.
The study was supported by the National Health Service Foundation Trust. Dr. Sommerfeld reported having no relevant financial disclosures.
SOURCE: Sommerfeld SA et al. EHA Congress, Abstract PS930.